NCT03159585View on ClinicalTrials.gov

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

June 4, 2019

Study Completion Date

June 4, 2019

Conditions
Liver Cancer Stage IVGastric Cancer Stage IVEsophageal Cancer, Stage IVBone and Soft Tissue TumorsBreast Cancer Stage IVBladder Carcinoma Stage IVProstate Carcinoma Stage IVThyroid Cancer Stage IVOvarian Cancer Stage IVSolid Tumor
Interventions
DRUG

TAEST16001

After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001

Trial Locations (1)

510282

Zhujiang Hospital of Southern Mediacl University, Guangzhou

All Listed Sponsors
collaborator

Xiangxue Life Science Research Center

UNKNOWN

collaborator

Guangdong Xiangxue Precision Medical Technology Co., Ltd.

INDUSTRY

collaborator

Xiangxue Pharmaceutical

OTHER

lead

Zhujiang Hospital

OTHER

NCT03159585 - To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | Biotech Hunter | Biotech Hunter